ReviewCancers2019
Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer-Just About Ready for Prime-Time?
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 111 citations in OpenAlex.
- Distinct Tumor-Immune Ecologies in Patients with Lung Cancer Predict Progression and Define a Clinical Biomarker of Therapy Response.Cancer research · 2026Article
- Label-Efficient Deep Color Deconvolution of Brightfield Multiplex IHC Images.IEEE transactions on medical imaging · 2026Article
- Comparison of QuPath and HALO Platforms for Analysis of the Tumor Microenvironment in Prostate Cancer.Laboratory investigation; a journal of technical methods and pathology · 2025Article
- Toward universal immunofluorescence normalization for multiplex tissue imaging with UniFORM.Cell reports methods · 2025Article
- Spatial phenotyping of human bronchial airways in obstructive lung disease.Respiratory research · 2025Article
- Review
- A predictive model for the transformation from cervical inflammation to cancer based on tumor immune-related factors.Frontiers in immunology · 2025Article
- Advancements in pathology: Digital transformation, precision medicine, and beyond.Journal of pathology informatics · 2025Review
- Exploring Multiplex Immunohistochemistry (mIHC) Techniques and Histopathology Image Analysis: Current Practice and Potential for Clinical Incorporation.Cancer medicine · 2025Review
- Digital analysis of the prostate tumor microenvironment with high-order chromogenic multiplexing.Journal of pathology informatics · 2024Article
- Current challenges and practical aspects of molecular pathology for non-small cell lung cancers.Virchows Archiv : an international journal of pathology · 2024Review
- Training immunophenotyping deep learning models with the same-section ground truth cell label derivation method improves virtual staining accuracy.Frontiers in immunology · 2024Article
- Multiplex Intraoperative Rapid Immunohistochemistry with Noncontact Antibody Mixing for Distinguishing the Histologic Phenotype of Lung Cancer.Pathobiology : journal of immunopathology, molecular and cellular biology · 2024Observational
- Quantitative multiplexed imaging technologies for single-cell analysis to assess predictive markers for immunotherapy in thoracic immuno-oncology: promises and challenges.British journal of cancer · 2023Review
- Unsupervised Stain Decomposition via Inversion Regulation for Multiplex Immunohistochemistry Images.Proceedings of machine learning research · 2023Article
- Companion diagnostic requirements for spatial biology using multiplex immunofluorescence and multispectral imaging.Frontiers in molecular biosciences · 2023Review
- CTC-5: A novel digital pathology approach to characterise circulating tumour cell biodiversity.Heliyon · 2023Article
- The Role of Pathology-Based Methods in Qualitative and Quantitative Approaches to Cancer Immunotherapy.Cancers · 2022Review
- A lncRNA signature associated with tumor immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma.Nature communications · 2022Article
- Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As targeted molecular therapies and immuno-oncology have become pivotal in the management of patients with lung cancer, the essential requirement for high throughput analyses and clinical validation of biomarkers has become even more intense, with response rates maintained in the 20%⁻30% range. Moreover, the list of treatment alternatives, including combination therapies, is rapidly evolving. The molecular profiling and specific tumor-associated immune contexture may be predictive of response or resistance to these therapeutic strategies. Multiplexed immunohistochemistry is an effective and proficient approach to simultaneously identify specific proteins or molecular abnormalities, to determine the spatial distribution and activation state of immune cells, as well as the presence of immunoactive molecular expression. This method is highly advantageous for investigating immune evasion mechanisms and discovering potential biomarkers to assess mechanisms of action and to predict response to a given treatment. This review provides views on the current technological status and evidence for clinical applications of multiplexing and how it could be applied to optimize clinical management of patients with lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.